WNT Stock Overview
A biotech company, develops therapies to prevent the metastatic process.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
WntResearch AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.89 |
| 52 Week High | SEK 21.60 |
| 52 Week Low | SEK 0.70 |
| Beta | 0.59 |
| 11 Month Change | -0.89% |
| 3 Month Change | -93.20% |
| 1 Year Change | -95.06% |
| 33 Year Change | -98.32% |
| 5 Year Change | -99.88% |
| Change since IPO | -99.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| WNT | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0.7% | -3.4% | -2.3% |
| 1Y | -95.1% | 29.7% | 21.0% |
Return vs Industry: WNT underperformed the Swedish Biotechs industry which returned 29.7% over the past year.
Return vs Market: WNT underperformed the Swedish Market which returned 21% over the past year.
Price Volatility
| WNT volatility | |
|---|---|
| WNT Average Weekly Movement | 30.0% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in SE Market | 10.8% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: WNT's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: WNT's weekly volatility has increased from 24% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2 | Per Goran Norlen | www.wntresearch.com |
WntResearch AB, a biotech company, develops therapies to prevent the metastatic process. The company develops Foxy-5, a peptide, which is in Phase II clinical trials that reduced the risk of metastasis in patients with colon cancer. It is also developing Box-5, a WNT5A antagonist for the treatment of malignant melanoma, and pancreatic and gastric cancer.
WntResearch AB Fundamentals Summary
| WNT fundamental statistics | |
|---|---|
| Market cap | SEK 7.74m |
| Earnings (TTM) | -SEK 41.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs WNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WNT income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 41.00m |
| Earnings | -SEK 41.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 21, 2024
| Earnings per share (EPS) | -4.73 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did WNT perform over the long term?
See historical performance and comparison